Immunotherapy of neuromyelitis optica.
Neuromyelitis optica (NMO) is a chronic inflammatory disease of the central nervous system that affects the optic nerves and spinal cord resulting in visual impairment and myelopathy. There is a growing body of evidence that immunotherapeutic agents targeting T and B cell functions, as well as active elimination of proinflammatory molecules from the peripheral blood circulation, can attenuate disease progression. In this review, we discuss the immunotherapeutic options and the treatment strategies in NMO. We also analyze the pathogenic mechanisms of the disease in order to provide recommendations regarding treatments.
Department of Neurological Sciences, Multiple Sclerosis Center, Rush University Medical Center, 1725 W. Harrison Street, Suite 309, Chicago, IL 60612, USA.
Benjamin
B
Bienia
Department of Neurological Sciences, Multiple Sclerosis Center, Rush University Medical Center, 1725 W. Harrison Street, Suite 309, Chicago, IL 60612, USA.
Roumen
R
Balabanov